Mind Medicine (MindMed) (MNMD) to Release Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period last year, the business earned ($0.59) earnings per share. On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Price Performance

NASDAQ MNMD traded up $0.34 on Friday, hitting $6.93. The company had a trading volume of 787,661 shares, compared to its average volume of 1,390,627. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The company's fifty day moving average price is $6.13 and its 200-day moving average price is $6.95. The company has a market capitalization of $522.30 million, a PE ratio of -3.07 and a beta of 2.54. Mind Medicine has a 12-month low of $4.70 and a 12-month high of $10.44.

Analysts Set New Price Targets

MNMD has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Robert W. Baird decreased their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Finally, Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an "outperform" rating and a $23.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $25.11.

Insider Buying and Selling

In related news, insider Daniel Karlin sold 6,836 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $46,074.64. Following the completion of the transaction, the insider now owns 446,177 shares of the company's stock, valued at approximately $3,007,232.98. This trade represents a 1.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert Barrow sold 21,208 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the sale, the chief executive officer now directly owns 856,556 shares in the company, valued at approximately $5,773,187.44. The trade was a 2.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,391 shares of company stock valued at $204,835. 2.26% of the stock is currently owned by insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.